Editorial
|
| Deregulation of the CDX2KLF4 axis in acute myeloid leukemia and colon cancer |
|
https://doi.org/10.18632/oncotarget.896
|
| 174-175 |
|
| Unexpected Outcomes of CDK4/6 Inhibition |
|
https://doi.org/10.18632/oncotarget.912
|
| 176-177 |
|
| Signaling networks network pathology and computational chemotherapy |
|
https://doi.org/10.18632/oncotarget.911
|
| 178-179 |
|
| Allosteric activation of PI3Kα by oncogenic mutations |
|
https://doi.org/10.18632/oncotarget.913
|
| 180-181 |
|
| Microbial Oncotarget: BacterialProduced Butyrate Chemoprevention and Warburg Effect |
|
https://doi.org/10.18632/oncotarget.915
|
| 182-183 |
Research Papers
|
| Calceineffluxing human colon cancer cells are enriched for selfrenewal capacity and depend on βcatenin |
|
https://doi.org/10.18632/oncotarget.883
|
| 184-191 |
|
| HPV16 E5 and KGFR/FGFR2b interplay in differentiating epithelial cells |
|
https://doi.org/10.18632/oncotarget.803
|
| 192-205 |
|
| TRAIL induces apoptosis in oral squamous carcinoma cells: a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5 |
|
https://doi.org/10.18632/oncotarget.813
|
| 206-217 |
|
| Targeted alphatherapy using [Bi213]antiCD20 as novel treatment option for radio and chemoresistant nonHodgkin lymphoma cells |
|
https://doi.org/10.18632/oncotarget.817
|
| 218-230 |
|
| ComedoDCIS is a precursor lesion for basallike breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup |
|
https://doi.org/10.18632/oncotarget.818
|
| 231-241 |
|
| In Vitro and in Vivo Antitumor Activity of miR221/222 Inhibitors in Multiple Myeloma |
|
https://doi.org/10.18632/oncotarget.820
|
| 242-255 |
|
| Ras inhibition boosts galectin7 at the expense of galectin1 to sensitize cells to apoptosis |
|
https://doi.org/10.18632/oncotarget.844
|
| 256-268 |
|
| Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression |
|
https://doi.org/10.18632/oncotarget.852
|
| 269-276 |
|
| Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models |
|
https://doi.org/10.18632/oncotarget.859
|
| 277-288 |
|
| TAp73βmediated suppression of cell migration requires p57Kip2 control of actin cytoskeleton dynamics |
|
https://doi.org/10.18632/oncotarget.833
|
| 289-297 |
|
| DNAintercalators Causing Rapid Reexpression of Methylated and Silenced Genes in Cancer Cells |
|
https://doi.org/10.18632/oncotarget.863
|
| 298-309 |
|
| BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib GSK2118436 and whole exomic sequencing for analysis of acquired resistance |
|
https://doi.org/10.18632/oncotarget.864
|
| 310-315 |
|
| Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib |
|
https://doi.org/10.18632/oncotarget.867
|
| 316-328 |
|
| Luteolin is a novel p90 ribosomal S6 kinase RSK inhibitor that suppresses Notch4 signaling by blocking the activation of Ybox binding protein1 YB1 |
|
https://doi.org/10.18632/oncotarget.834
|
| 329-345 |
|
| Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and selfrenewal |
|
https://doi.org/10.18632/oncotarget.868
|
| 346-361 |
|
| Actinbinding protein alphaactinin 4 ACTN4 is a transcriptional coactivator of RelA/p65 subunit of NFkB |
|
https://doi.org/10.18632/oncotarget.901
|
| 362-373 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
